Beyond strategic partnerships with industry, we maintain a continuing interest in establishing collaborative research agreements with academia, government and non-governmental organizations.

To learn more about partnering and collaboration opportunities with Sarepta, please contact us.




Genethon logo (1).jpg


In June 2017, Sarepta Therapeutics signed a collaboration with Genethon, a non-profit R&D organization dedicated to the development of biotherapies for orphan genetic diseases from research to clinical validation. Genethon employs one of the largest research and clinical groups in the world working to advance rare disease therapies and is affiliated with Europe’s largest cGMP vector manufacturing facility, YposKesi, located in Evry (Essonne).

Under the terms of the research collaboration, Sarepta and Genethon will jointly develop treatments for DMD. Genethon’s micro-dystrophin gene therapy approach, which can target the majority of boys with DMD, has demonstrated robust gene expression in a large GRMD model. Moreover, data show for the first time a systemic therapeutic effect in DMD dogs using a rAAV2/8 micro-dystrophin gene therapy approach without immunosuppressive treatment. The results were published in the July 25, 2017 online issue of Nature Communications. Click the video below for more information.


Scientists restore muscle strength in dogs using micro-dystrophin gene therapy




In 2015, we entered into a four-year collaborative research agreement to establish the Sarepta Translational Laboratory with Murdoch University, Perth, Western Australia. The laboratory, led by Murdoch University professors, Steve Wilton Ph.D. and Sue Fletcher, Ph.D., will explore the applicability of the Company's phosphorodiamidate morpholino oligomer (PMO) technology for rare neuromuscular and CNS diseases. As part of the collaborative agreement, Sarepta will have exclusive rights to license technology and/or products resulting from the research projects.



In 2013, we entered into an exclusive, worldwide licensing agreement with the University of Western Australia (UWA) for intellectual property rights to support the development of exon-skipping drug candidates for the treatment of Duchenne muscular dystrophy (DMD). The agreement grants us rights to UWA's extensive patent portfolio in DMD and enables us to build out our exon-skipping pipeline with new candidates to address the majority of patients with DMD worldwide.